TY - JOUR
T1 - Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries
T2 - A survey
AU - Ahmadzay, Zohra F.
AU - Heberg, Jette
AU - Jørgensen, Jacob B.
AU - Ørnbjerg, Lykke M.
AU - Østergaard, Mikkel
AU - Møller-Bisgaard, Signe
AU - Michelsen, Brigitte
AU - Loft, Anne Gitte
AU - Jones, Gareth T.
AU - Hellamand, Pasoon
AU - Scherer, Almut
AU - Nissen, Michael J.
AU - Pavelka, Karel
AU - Závada, Jakub
AU - Laas, Karin
AU - Vorobjov, Sigrid
AU - Nordström, Dan
AU - Sokka-Isler, Tuulikki
AU - Regierer, Anne C.
AU - Reich, Andreas
AU - Gudbjornsson, Bjorn
AU - Thorarinsdottir, Katrin
AU - Iannone, Florenzo
AU - Favalli, Ennio Giulio
AU - Van De Sande, Marleen
AU - Provan, Sella Aarrestad
AU - Kvien, Tore K.
AU - Rodrigues, Ana Maria
AU - Gonçalves, Cátia F.
AU - Codreanu, Catalin
AU - Mogosan, Corina
AU - Rotar, Ziga
AU - Prikmajer, Katja Perdan
AU - Castrejon, Isabel
AU - Otero-Varela, Lucía
AU - Di Giuseppe, Daniela
AU - Wallman, Johan K.
AU - Ciurea, Adrian
AU - Möller, Burkhard
AU - Kenar-Artln, Gökçe
AU - Ylldlrlm, Tuba Demirci
AU - MacFarlane, Gary J.
AU - Rotariu, Ovidiu
AU - Glintborg, Bente
AU - Hetland, Merete Lund
N1 - Funding Information:
This work was supported by Novartis Pharma AG. EuroSpA was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript.
Publisher Copyright:
© 2024 The Author(s).
PY - 2024
Y1 - 2024
N2 - Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and comorbidities. International collaboration is required to ensure statistical power and to enhance generalizability. The first step forward is identifying which data are currently being collected. Across 17 registries participating in the European Spondyloarthritis Research Collaboration (EuroSpA), we aimed to map recording practices for NMMs, comorbidities and safety outcomes in patients with PsA and axSpA. Methods: Through a survey with 4,420 questionnaire items, we explored the recording practices of 58 pre-defined conditions (i.e. NMMs, comorbidities and safety outcomes) covering 10 disease areas. In all registries we mapped for each condition whether it was recorded, the recording procedure and the potential to identify it through linkage to other national registries. Results: Conditions were generally recorded at entry into the registry and clinical follow-up visits using a pre-specified list or a coding system. Most registries recorded conditions within the following disease areas: NMMs (number of registries, n = 15-16), cardiovascular diseases (n = 10-14), gastrointestinal diseases (n = 12-13), infections (n = 10-13) and death (n = 14). Nordic countries had the potential for data linkage and generally had limited recording of conditions in their registry, while other countries had comprehensive recording practices. Conclusion: A wide range of conditions were consistently recorded across the registries. The recording practices of many conditions and disease areas were comparable across the registries. Our findings support the potential for future collaborative research.
AB - Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and comorbidities. International collaboration is required to ensure statistical power and to enhance generalizability. The first step forward is identifying which data are currently being collected. Across 17 registries participating in the European Spondyloarthritis Research Collaboration (EuroSpA), we aimed to map recording practices for NMMs, comorbidities and safety outcomes in patients with PsA and axSpA. Methods: Through a survey with 4,420 questionnaire items, we explored the recording practices of 58 pre-defined conditions (i.e. NMMs, comorbidities and safety outcomes) covering 10 disease areas. In all registries we mapped for each condition whether it was recorded, the recording procedure and the potential to identify it through linkage to other national registries. Results: Conditions were generally recorded at entry into the registry and clinical follow-up visits using a pre-specified list or a coding system. Most registries recorded conditions within the following disease areas: NMMs (number of registries, n = 15-16), cardiovascular diseases (n = 10-14), gastrointestinal diseases (n = 12-13), infections (n = 10-13) and death (n = 14). Nordic countries had the potential for data linkage and generally had limited recording of conditions in their registry, while other countries had comprehensive recording practices. Conclusion: A wide range of conditions were consistently recorded across the registries. The recording practices of many conditions and disease areas were comparable across the registries. Our findings support the potential for future collaborative research.
KW - biological therapies
KW - comorbidity
KW - DMARDs
KW - JAK inhibitors
KW - multimorbidity
KW - routinely collected data
KW - spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=85210915042&partnerID=8YFLogxK
U2 - 10.1093/rap/rkae135
DO - 10.1093/rap/rkae135
M3 - Article
AN - SCOPUS:85210915042
SN - 2514-1775
VL - 8
JO - Rheumatology Advances in Practice
JF - Rheumatology Advances in Practice
IS - 4
M1 - rkae135
ER -